FDA approves Moderna's mRNA RSV vaccine for older adults

The US Food and Drug Administration has approved a new vaccine to protect older individuals from respiratory syncytial virus (RSV). The vaccine, developed by Moderna and called mResvia, is the first mRNA vaccine for RSV to receive FDA approval. It is the third RSV vaccine for people aged 60 and older to be approved by the FDA. RSV is a common virus that typically causes mild infection but can be dangerous for older individuals, young children, and those with underlying health conditions. The approval of Moderna’s vaccine was based on clinical trial data showing its efficacy in preventing lower respiratory tract disease. The company expects the vaccine to be available for eligible groups in the US in time for the 2024-25 RSV season.